Antibody Discovery Market

Antibody Discovery Market (5th Edition): Focus on Services and Platforms - Distribution by Type of Service Offered, Antibody Discovery Method, Type of Antibody Generated, Nature of Antibody Generated, Therapeutic Areas and Key Geographies: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Published
    September 2023

  • Pages
    552

  • View Count
    68935

Example Insights

Antibody-Discovery-Services-and-Platforms-Market-Context-thumb Antibody-Discovery-Services-and-Platforms-Market-Distribution-by-Geography-thumb Antibody-Discovery-Services-and-Platforms-Market-List-of-Antibody-Discovery-Service-Providers-thumb Antibody-Discovery-Services-and-Platforms-Market-Distribution-by-Company-Size-thumb
Antibody-Discovery-Services-and-Platforms-Market-Company-Competitiveness-Analysis-thumb Antibody-Discovery-Services-and-Platforms-Market-Detailed-Profiles-thumb Antibody-Discovery-Services-and-Platforms-Market-Discovery-Platform-Providers-thumb Antibody-Discovery-Services-and-Platforms-Market-Platforms-and-Technologies-thumb
Antibody-Discovery-Services-and-Platforms-Market-Technology-Competitiveness-Analysis-thumb Antibody-Discovery-Services-and-Platforms-Market-Partnerships-and-Collaborations-thumb Antibody-Discovery-Services-and-Platforms-Market-Funding-and-Investment-Analysis-thumb Antibody-Discovery-Services-and-Platforms-Market-Licensing-Deal-Structures-thumb
Antibody-Discovery-Services-and-Platforms-Market-Examples-of-Deal-Financials-thumb Antibody-Discovery-Services-and-Platforms-Market-Market-Trends-and-Outlook-thumb Antibody-Discovery-Services-and-Platforms-Market-Antibody-Discovery-Services-Market-thumb Antibody-Discovery-Services-and-Platforms-Market-Distribution-by-Therapeutic-Area-thumb
Antibody-Discovery-Services-and-Platforms-Market-Likely-Growth-Scenarios-thumb      

 

Report Description

In most of the cases, hit generation constitutes the majority of the R&D expenditure, leading to around 40% - 50% of the total cost, thus it is expected to hold the majority of the share of the antibody discovery services market.

-- President, US-based small sized company

Antibody Discovery Services and Platforms Market Overview

The global antibody discovery services and platforms market size is estimated to be worth over $1.6 billion in 2023 and is expected to grow at a compounded annual growth rate (CAGR) of 12.0% during the forecast period. The usual drug development process, beginning from discovery to commercialization of a clinically validated product spans around 10-15 years and requires investments of over $2 billion. However, despite the extensive efforts and investments, over 90% of the drug candidates fail in clinical trials. In order to streamline the drug development processes, reduce timelines, and mitigate financial risks associated with failed trials, pharmaceutical players are increasingly outsourcing various aspects of their discovery-stage operations to specialized contract research organizations (CROs). By leveraging the capabilities of such antibody CRO, companies engaged in the antibody discovery market can optimize internal resource utilization and cost saving. Such strategic collaborations allow antibody discovery companies to tap into a global network of scientific talent, which leads to the enhancement of the overall efficiency and success rate of bringing novel antibody-based therapeutics to the market.

Since the approval of the first monoclonal antibody-based therapy, Orthoclone OKT3®, in 1986, such antibodies have evolved into a versatile class of biopharmaceuticals, undergoing significant advancements in engineering, diversification of formats, and innovative discovery methods. Currently, more than 160 monoclonal antibodies have been approved by the various regulatory agencies around the world to be used in humans for the treatment of various diseases, including cancer, chronic inflammatory diseases, infectious diseases and cardiovascular diseases. Some of the recently approved monoclonal antibody therapies include (in reverse chronological order of their approval date) ELREXFIO™ (August 2023), TALVEY™ (August 2023), Rystiggo® (June 2023), COLUMVI® (June 2023) and EPKINLY™ (May 2023). Owing to the complexities associated with the discovery of such monoclonal antibodies, many firms are opting to license and utilize specialized antibody discovery platforms and technologies. Further, given the rising demand for antibody based therapeutics and growing preference for outsourcing, we are led to believe that the opportunity for antibody discovery services and platforms is likely to increase at a significant growth rate in the foreseen future.

Key Market Insights

The Antibody Discovery Services and Platforms Market (5th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based, Transgenic Animal based), Type of Antibody Generated (Monoclonal Antibodies, Bispecific Antibodies and Others), Nature of Antibody Generated (Chimeric, Human, Humanized and Murine), Type of Therapeutic Areas (Cardiovascular Disorders, Immunological Disorders, Infectious Disorders, Neurological Disorders, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities within the antibody drug discovery services and platforms market during the forecast period. The market report highlights the efforts of the various stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the antibody drug discovery services and platforms market are briefly discussed below.

Increasing Reliance on Outsourcing of Antibody Discovery to Contract Research Organizations

Outsourcing has been a strategic deployment of the pharmaceutical industry, for the past several decades, where companies delegate their various tasks to external vendors, in order to improve innovation and efficiency of their candidates. The contract research and manufacturing organizations accelerate the development timelines and ensure compliance with stringent regulations through their expertise. These organizations offer risk sharing and transfer and enhance adaptability to market growth. The growing interest in outsourcing of biopharmaceutical operations can be attributed to the need for rapid market access and the rising development costs. As pharmaceutical companies continue to embrace this trend, outsourcing is expected to continue to evolve the industry's landscape, optimizing operations and driving progress in therapeutic innovations.

Key Drivers of the Global Market for Antibody Discovery Services and Technologies

Recent advancements in biotechnology, increasing demand for targeted therapies, ever-increasing prevalence of chronic diseases, increase in R&D expenditure in pharma and growing trend for outsourcing antibody discovery are some of the key drivers of the antibody drug discovery services and antibody discovery platforms market growth. In addition, the increasing number of collaborations between academic institutions and antibody discovery companies engaged in this industry contributes to the market growth. It is interesting to note that recently, in May 2023, Nona Biosciences signed an agreement with ModeX Therapeutics in order to integrate Harbour Mice® technology into the latter’s MSTAR platform for the discovery of improved treatment options. 

Market Trends: Increase in Funding Activity in the Antibody Drug Discovery Service and Platform Domain

Owing to the increase in applications of antibody drug discovery services and platforms, the industry has garnered significant interest from investors, which has resulted in a strong spur in investment activity in this market. For instance, in January 2023, IASO Biotherapeutics USD 75 million in a venture series C round. Further, it is worth highlighting that, in the past two years, four antibody discovery companies (Apexigen, Biocytogen, Shandong Boan Biotechnology and Twist Bioscience) have collectively raised over USD 375 million through initial public offerings. The funds raised by the companies operating in antibody discovery market will continue to advance the development of next generation antibody discovery platforms, which will support the development of novel antibody-based therapeutics driving the market growth over the forecast period.

Furthermore, several companies are entering into mergers and acquisitions to expand the service offerings in the antibody discovery market. In March 2023, Twist Bioscience announced the launch of its antibody discovery services under the Twist Biopharma Solutions subsidiary. The company acquired Abveris, an antibody discovery CRO in 2022 to gain hold of its single cell screening and hybridoma approach.

Recent Trends on the Licensing of Antibody Discovery Platforms

Licensing of antibody discovery platforms enables the companies to access innovative tools and methods for developing therapeutic antibodies, allowing firms to leverage specialized expertise and expand their R&D capabilities by avoiding the spend on the technology. Recent trends highlight a growing emphasis on collaborations and partnerships between academic institutes, biotechnology startups, and established pharmaceutical companies. Various key players engaged in this market have undertaken various initiatives to out-license / in-license several such antibody discovery platforms. For instance, recently, in June 2023, AbTherx entered into an agreement with Gilead Sciences in order to in-license latter’s novel transgenic mouse technology, named Atlas™ Mice. In addition, in January 2023, Hummingbird Bioscience entered into an agreement with Synaffix in order to utilize Synaffix’s proprietary technologies, GlycoConnect™ and HydraSpace™. 
 
Market Size: Key Segments of the Antibody Drug Discovery Services and Platforms Market

The global market size for antibody drug discovery services and platforms is anticipated to grow at an annualized CAGR of 11.0%, during the forecast period, 2023-2035. At present, the hit generation segment captures the largest market share (40%) of the overall antibody discovery services and platforms market. The hit generation step, which usually employs high-throughput screening and computational methods to accelerate drug discovery, generally accounts for the major proportion of the R&D expenditure in the antibody discovery processes. Given its significance in antibody discovery processes, this trend is unlikely to change during the forecast period. Further, in terms of the antibody discovery method, hybridoma method captures the largest market share (over 30%) of the overall antibody discovery services and platforms market. Owing the capability of hybridoma method to lead the fusion of antibody-producing B cells with myeloma cells in order to create immortalized cell lines capable of continuous antibody manufacturing, this method has proven valuable for generating targeted antibodies for various therapeutic and research applications.

Regional Analysis: North America Holds the Largest Market Share of Antibody Drug Discovery Services and Platforms Market

Presently, close to 40% of the market is captured by companies based in North America. Driven by the rising interest in advanced antibody discovery platforms and increasing need for outsourcing in the pharmaceutical industry, the market size for antibody drug discovery services and platforms in North America is anticipated to grow at a CAGR of 12%, during the forecast period, 2023-2035. Several factors contribute to the region’s dominance in this domain, which include the presence of big pharma companies with well-established R&D divisions that foster innovation and drive the demand for advanced antibody discovery platforms. 

Key Players Engaged in Antibody Discovery Services and Platforms Market 

Examples of key players (which have also been profiled in this market report) engaged in antibody discovery market include (in alphabetical order) Ablexis, Antibody Solutions, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, ImmunoPrecise, Mabsilico, Myrio Therapeutics, Nona Biosciences, Rockland Immunochemicals, Synbio technologies and WuXi Biologics. This market report includes an easily searchable excel database of all the antibody discovery service providers and antibody discovery platform providers worldwide.

Recent Developments in Antibody Discovery Services and Platforms Market

Several recent developments have taken place in the field of antibody discovery in terms of both services and platforms. We’ve outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis.

  • In June 2023, AbTherx announced the launch of its transgenic mouse-based antibody discovery platform, Atlas™ Mice. 
  • In June 2023, another China based company Sanyou Biopharmaceuticals launched its Sanyou Super Trillion Common Light Chain Antibody Discovery Platform, which supports the discovery of bispecific antibody formats.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in antibody discovery services market, across different segments as defined in the below table:

Key Report Attributes Details

Historical Trend

2017 – 2021

Base Year

2022

Forecast Period

2023 – 2035

Market Size 2023

$1.6 Billion

CAGR

12.0%

Type of Service Offered

  • Antigen Designing
  • Hit Generation
  • Lead Selection
  • Lead Optimization
  • Lead Characterization

Antibody Discovery Method

  • Hybridoma Based
  • Library Based
  • Single Cell Based
  • Transgenic Animal Based

Type of Antibody Generated

  • Monoclonal Antibodies
  • Bispecific Antibodies
  • Others

Nature of Antibody Generated

  • Chimeric
  • Human
  • Humanized
  • Murine

Type of Therapeutic Area

  • Cardiovascular Disorders
  • Immunological Disorders
  • Infectious Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Others

Key Geographical Regions

  • North America
  • Europe
  • Asia
  • Latin America
  • Middle East and North Africa
  • Rest of the World

Key Companies Profiled

  • Ablexis
  • Antibody Solutions
  • ChemPartner
  • Creative Biolabs
  • GenScript
  • Genmab
  • Harbour BioMed
  • ImmunoPrecise
  • MabSilico
  • Myrio Therapeutics
  • Nona Biosciences
  • Rockland Immunochemicals
  • Synbio technologies 
  • WuXi Biologics

(Full list of over 350 companies captured available in the report)

Customization Scope

15% Free Customization Option

PowerPoint Presentation (Complimentary)

Available

Excel Data Packs (Complimentary)

  • Antibody Discovery Service Providers: Current Market Landscape
  • Antibody Discovery Platforms: Current Market Landscape
  • Company Competitiveness Analysis
  • Technology Competitiveness Analysis
  • Partnerships and Collaborations Analysis
  • Funding and Investment Analysis
  • Licensing Deal Structure
  • Antibody Discovery Service Providers: Market Forecast and Opportunity Analysis
  • Antibody Discovery Platforms / Technologies: Market Forecast and Opportunity Analysis

The market research report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different geographies. Amongst other elements, the market report features:

  • A preface providing an introduction to the full report, Antibody Discovery Services and Platforms Market (5th Edition), 2017-2022 (Historical Trends) and 2023-2035 (Forecasted Estimates).
  • An outline of the systematic research methodology adopted to conduct the study on antibody discovery services and platforms market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • An overview of economic factors that impact the overall antibody discovery services and platforms market, which include historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the key insights captured in our research. It offers a high-level view on the current state of the antibody discovery services and platforms market and its likely evolution in the short to mid and long term.
  • A general introduction of antibodies, featuring details on their historical background, structure, isotypes, mechanism of action and applications. It also emphasizes the different types of antibodies, namely monoclonal, bispecific and polyclonal antibodies.
  • A detailed overview on the antibody discovery process and the various methods used in the discovery of these therapeutic biomolecules. It also features a comparison of different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.
  • A general overview of the current market landscape of over 160 service providers that are currently active in the antibody discovery services market. It features a detailed analysis of these service providers based on several parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).
  • An insightful competitiveness analysis of antibody discovery service providers that we came across during our research. The analysis compares the companies based on their years of experience, number of platforms, number of antibody discovery services offered, types of antibody discovery methods adopted, type of antibody formats generated, type of application areas. The chapter also presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered by the platform providers.
  • Detailed profiles of the stakeholders that are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, recent developments and an informed future outlook.
  • An overview of the current market landscape of over 290 antibody discovery platforms, including in-depth analyses on type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others), type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others) and animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others). In addition, the chapter highlights insightful analyses of 190+ antibody discovery platform providers based on their company details such as year of establishment, company size and location of headquarters. 
  • An insightful competitiveness analysis of antibody discovery technologies, highlighting the leading players in this market, taking into consideration the supplier power (based on the year of establishment of the platform provider) and key specifications of the platforms, such as type of antibody discovered, compatibility of antibodies in human, number of deals signed for a particular platform (2015-2023).  
  • Detailed profiles of the stakeholders, which actively provide access / licenses to their antibody discovery platform / technology to other companies. Each company profile includes a brief overview of the company, details on antibody discovery platforms / technology, recent developments and an informed future outlook.
  • An in-depth analysis and discussion on the various partnerships that have been inked between the players in antibody discovery services and platforms market in the time period between 2021 and 2023. It includes a brief description of partnership models (such as acquisitions, clinical trial agreements, mergers, multipurpose agreements, product / technology licensing agreements, product development and commercialization agreements, research and development agreements, service agreements, technology integration agreements, technology utilization agreements) adopted by the stakeholders.
  • An analysis of the funding and investments made in antibody discovery services and platforms market during the period 2016-2023, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of antibody discovery. 
  • An insightful deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.
  • A SWOT analysis on antibody humanization services, highlighting industry-specific trends, key market drivers and challenges for players engaged in providing such services. In addition, the chapter presents a list of key players that perform antibody humanization and affinity maturation services along with information on their respective location and the methodology adopted by such players. Further, this chapter elaborates on the factors that are likely to influence the activities of companies engaged in offering such services.
  • Detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2022). It provides detailed profiles on top five drugs, namely Humira®, Keytruda®, Stelara®, Opdivo® and Darzalex®, including information on their historical sales, discovery process and methods.
  • An overview of future growth opportunities in the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have influence on the industry’s evolution over the coming decade.

One of the key objectives of the market report was to estimate the current opportunity and future growth potential for antibody discovery services and platforms market over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), type of antibody generated (monoclonal antibodies, bispecific antibodies and others), nature of antibody generated (chimeric, human, humanized and murine), type of therapeutic areas (cardiovascular disorders, immunological disorders, infectious disorders, neurological disorders, oncological disorders and others) and key geographical regions (North America, Europe and Asia, Latin America, Middle East and North Africa, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market growth.

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • John S Kenney (Founder and President, Antibody Solutions)
  • Guy Van Meter (Chief Business Officer, Adimab)
  • Kari Graber (Vice President of Commercial Services)
  • Anonymous (Chief Business Officer, US based Mid-sized Company)
  • Tracey Mullen (Former Chief Executive Officer, Abveris Antibody (acquired by Twist Bioscience))
  • Lisa Delouise (Founder and Chief Technology Officer, Nidus BioSciences)
  • Mark Kubik (Former Chief Business Officer, AvantGen)
  • Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
  • Giles Day (Co-founder and Former Chief Executive Officer, Distributed Bio)
  • Kevin Heyries (Co-founder and Former Lead of Business Development Strategy, AbCellera)
  • Sanjiban K Banerjee (Co-founder and Director, AbGenics Life Sciences)
  • Ignacio Pino (Co-founder and Chief Operating Officer, CDI Laboratories) 
  • Jeng Her (Chief Executive Officer, AP Biosciences) 
  • Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)
  • Debra Valsamis (Business Development Associate, Antibody Solutions)
  • Christel Iffland (Senior Vice President, Ligand Pharmaceuticals)
  • Aaron Sato (Former Chief Scientific Officer, LakePharma)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are antibody discovery services?

Answer: Antibody discovery services are service offerings of the pharmaceutical contract research organizations to assist in the identification of the antibody drug targets and development of antibodies.

Question 2: What are the methods of antibody discovery?

Answer: Antibody discovery utilizes various techniques, such as phage display, hybridoma technology, and next generation sequencing, to generate antibodies that can target specific antigens.

Question 3: What is the importance of antibody drug discovery services and platforms in the healthcare sector?

Answer: Antibody drug discovery services and platforms are vital in expediting the development of antibodies. Such offerings provide pharmaceutical companies with specialized expertise, advanced technologies, and cost efficiencies. Further, it helps to accelerate drug development and allows faster commercialization of a drug candidate.

Question 4: What is the likely market size of the antibody discovery services and platforms market?

Answer: The global antibody discovery services and platforms market is expected to be worth USD 32.1 billion by 2035.

Question 5: What is the estimated growth rate (CAGR) of the antibody discovery services and platforms market?

Answer: The global antibody discovery services and platforms market size is anticipated to grow at a compound annual growth rate (CAGR) of 12.0%, during the forecast period 2023-2035.

Question 6: Which region is likely to hold the largest market share in the global antibody discovery services and platforms market?

Answer: Currently, North America and Europe collectively hold 65% of the market share. However, in the long run, the market in Asia is expected to grow at a relatively faster pace.

Question 7: What is the trend of capital investments in the antibody discovery services and platforms market?

Answer: Owing to the lucrative market opportunity associated with antibody discovery services and platforms, several investors have collectively invested nearly USD 24 billion, during the period 2016-2023.

Question 8: Which antibody discovery step currently accounts for the largest market share in the antibody discovery services and platforms market?

Answer: At present, the hit generation segment captures the largest market share (40%) of the overall antibody discovery services and platforms market. This trend is unlikely to change during the forecast period.

Question 9: Which are the leading market segments in antibody discovery services and platforms market, in terms of antibody discovery method?

Answer: At present, the hybridoma segment captures the largest market share (over 30%) of the overall antibody discovery services and platforms market.

Question 10: What are the key factors contributing to the growth of antibody discovery services and platforms market?

Answer: The antibody discovery services and platforms market is likely to be driven by increasing demand for therapeutic antibodies, advancements in screening and computational methods, customization for personalized treatments, increasing number of strategic collaborations, emerging disease targets, and integration of data science and AI for improved efficiency.

Contents

Table Of Content

1. PREFACE
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations

2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. History of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies

5.6. Classification of Antibodies
5.6.1. Monoclonal Antibodies
5.6.2. Polyclonal Antibodies
5.6.3. Bispecific Antibodies

5.7. Applications of Antibodies
5.8. Concluding Remarks

6. ANTIBODY DISCOVERY: PROCESS AND METHODS
6.1. Chapter Overview
6.2. Antibody Discovery Process
6.2.1. Target Selection and Validation
6.2.2. Hit Generation
6.2.3. Lead Selection
6.2.4. Lead Optimization
6.2.4.1. Humanization
6.2.4.2. Affinity Maturation
6.2.4.3. Fc Engineering
6.2.5. Lead Characterization
6.2.6. Candidate Selection

6.3. Antibody Discovery Methods
6.3.1. Hybridoma Technology-based Method
6.3.2. In vitro Display Method
6.3.2.1. Phage Display
6.3.2.2. Yeast Display
6.3.2.3. Ribosomal Display
6.3.3. Transgenic Animal-based Method
6.3.4. Single B Cell-based Method
6.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques

6.4. Evolution of Monoclonal Antibodies
6.4.1. Fully Human Monoclonal Antibodies

6.5. Concluding Remarks

7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: List of Industry Players
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Service Offered
7.2.5. Analysis by Type of Antibody Discovered
7.2.6. Analysis by Type of Antibody Discovery Method
7.2.7. Analysis by Animal Model Used
7.2.8. Analysis by Type of Antibody Discovered and Type of Antibody Discovery Method
7.2.9. Analysis by Type of Antibody Discovery Services and Location of Headquarters
7.2.10. Analysis by Application Area

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies Grouped based on Company Size
8.4.1. Very Small Companies Offering Antibody Discovery Services
8.4.2. Small Companies Offering Antibody Discovery Services
8.4.3. Mid-sized Companies Offering Antibody Discovery Services
8.4.4. Large Companies Offering Antibody Discovery Services

8.5. Antibody Discovery Service Providers: Regional Capability
8.5.1. Antibody Discovery Service Providers based in North America
8.5.2. Antibody Discovery Service Providers based in Europe
8.5.3. Antibody Discovery Service Providers based in Asia

9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Antibody Discovery Service Providers in North America
9.2.1. Abwiz Bio
9.2.1.1. Company Overview
9.2.1.2. Recent Developments and Future Outlook

9.2.2. Aragen Bioscience (Subsidiary of GVK BIO)
9.2.2.1. Company Overview
9.2.2.2. Recent Developments and Future Outlook

9.2.3. Creative Biolabs
9.2.3.1. Company Overview
9.2.3.2. Recent Developments and Future Outlook

9.2.4. Distributed Bio
9.2.4.1. Company Overview
9.2.4.2. Recent Developments and Future Outlook

9.2.5. ImmunoPrecise Antibodies
9.2.5.1. Company Overview
9.2.5.2. Financial Information
9.2.5.3. Recent Developments and Future Outlook

9.2.6. Integral Molecular
9.2.6.1. Company Overview
9.2.6.2. Recent Developments and Future Outlook

9.2.7. LakePharma
9.2.7.1. Company Overview
9.2.7.2. Recent Developments and Future Outlook

9.2.8. Syd Labs
9.2.8.1. Company Overview
9.2.8.2. Recent Developments and Future Outlook

9.3. Antibody Discovery Service Providers in Europe
9.3.1. Abzena
9.3.1.1. Company Overview
9.3.1.2. Financial Information
9.3.1.3. Recent Developments and Future Outlook

9.3.2. BIOTEM
9.3.2.1. Company Overview
9.3.2.2. Recent Developments and Future Outlook

9.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
9.3.3.1. Company Overview
9.3.3.2. Recent Developments and Future Outlook

9.4. Antibody Discovery Service Providers in Asia and Rest of the World
9.4.1. ChemPartner
9.4.1.1. Company Overview
9.4.1.2. Recent Developments and Future Outlook

9.4.2. HD Biosciences
9.4.2.1. Company Overview
9.4.2.2. Recent Developments and Future Outlook

9.4.3. Viva Biotech
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Recent Developments and Future Outlook

9.4.4. WuXi Biologics
9.4.4.1. Company Overview
9.4.4.2. Financial Information
9.4.4.3. Recent Developments and Future Outlook

10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Antibody Discovery: List of Technologies and Platforms
10.2.1. Analysis by Type of Antibody Discovery Method
10.2.2. Analysis by Type of Antibody Discovered
10.2.3. Analysis by Animal Model Used
10.2.4. Analysis by Type of Antibody Discovery Method and Location of Headquarters
10.2.5. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered

10.3. Antibody Discovery Technologies: List of Industry Players
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Location of Headquarters
10.3.4. Most Active Players: Analysis by Number of Platforms

11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Antibody Discovery Technologies: Competitiveness Analysis
11.4.1. Antibody Discovery Technologies Offered by Companies based in North America
11.4.2. Antibody Discovery Technologies Offered by Companies based in Europe
11.4.3. Antibody Discovery Technologies Offered by Companies based in Asia and Rest of the World

12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
12.1. Chapter Overview
12.2. Harbour BioMed
12.2.1. Company Overview
12.2.2. Antibody Discovery Platforms Portfolio
12.2.3. Recent Developments and Future Outlook

12.3. ImmunoPrecise Antibodies
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Antibody Discovery Platforms Portfolio
12.3.4. Recent Developments and Future Outlook

12.4. Kymab
12.4.1. Company Overview
12.4.2. Antibody Discovery Platforms Portfolio
12.4.3. Recent Developments and Future Outlook

12.5. Ligand Pharmaceuticals
12.5.1. Company Overview
12.5.2. Financial Information
12.5.3. Antibody Discovery Platforms Portfolio
12.5.4. Recent Developments and Future Outlook

12.6. MorphoSys
12.6.1. Company Overview
12.6.2. Financial Information
12.6.3. Antibody Discovery Platforms Portfolio
12.6.4. Recent Developments and Future Outlook

13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. List of Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year of Partnership and Type of Partner
13.3.4. Analysis by Type of Antibody
13.3.5. Most Active Players: Analysis by Number of Partnerships
13.3.6. Most Popular Technologies: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.8. Intracontinental and Intercontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Antibody Discovery Service and Platform Providers: Funding and Investment
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Type of Funding
14.3.3. Analysis of Amount Invested by Year of Funding
14.3.4. Analysis by Year-wise Number of Funding Instances and Funding Amount
14.3.5. Most Active Players: Analysis by Number of Funding Instances
14.3.6. Most Active Players: Analysis by Amount Invested
14.3.7. Leading Investors: Analysis by Number of Funding Instances
14.3.8. Analysis by Year-wise Number of Funding Instances and Type of Player
14.3.9. Analysis by Year-wise Amount Invested and Type of Player
14.3.10. Analysis of Number of Funding Instances by Year of Establishment and Type of Player
14.3.11. Analysis by Geography
14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion

16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
16.3.1. Scenario Analysis
16.4. Key Market Segmentations
16..5. Dynamic Dashboard

17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.4. Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.5. Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.6. Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.7. Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation and Validation

18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.4. Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.5. Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.6. Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.7. Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.8. Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.9. Data Triangulation and Validation

19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Humanized: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.4. Human: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.5. Chimeric: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.6. Murine: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation

20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.4. Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.5. Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.6. Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.7. Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.8. Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.9. Data Triangulation and Validation

21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.6. Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.7. Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.8. Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.9. Data Triangulation and Validation

22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
22.3.1. Scenario Analysis

22.4. Key Market Segmentations
22.5. Dynamic Dashboard

23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.4. Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.5. Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.6. Data Triangulation and Validation

24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.6. Data Triangulation and Validation

25. LICENSING DEAL STRUCTURE
25.1. Chapter Overview
25.2. Key Parameters
25.3. Assumptions and Methodology
25.3.1. Overall Cash Flow for Licensee Companies
25.3.1.1. Investments Made by a Licensee
25.3.1.2. Revenues Earned by a Licensee
25.3.2. Overall Cash Flow for Licensor Companies
25.3.2.1. Investments Made by a Licensor
25.3.2.2. Revenues Earned by a Licensor

25.4. Key Analytical Outputs
25.4.1. Scenario 1: Variation of Upfront and Milestone Payments
25.4.2. Scenario 2: Variation of Upfront Payments and Sales-based Royalties
25.4.3. Scenario 3: Variation of Milestone Payments and Sales-based Royalties

26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS
26.1. Chapter Overview
26.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: List of Players
26.3. Antibody Humanization Service Providers: SWOT Analysis
26.3.1. Strengths
26.3.2. Weaknesses
26.3.3. Opportunities
26.3.4. Threats

27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
27.1. Chapter Overview
27.2. Humira® (Adalimumab)
27.2.1. Drug Overview
27.2.2. Discovery Process and Method
27.2.3. Historical Sales

27.3. Keytruda® (Pembrolizumab)
27.3.1. Drug Overview
27.3.2. Discovery Process and Method
27.3.3. Historical Sales

27.4. Stelara® (Ustekinumab)
27.4.1. Drug Overview
27.4.2. Discovery Process and Method
27.4.3. Historical Sales

27.5. Opdivo® (Nivolumab)
27.5.1. Drug Overview
27.5.2. Discovery Process and Method
27.5.3. Historical Sales

27.6. Darzalex® (Daratumumab)
27.6.1. Drug Overview
27.6.2. Discovery Process and Method
27.6.3. Historical Sales

28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY28.1. Chapter Overview
28.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
28.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
28.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
28.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
28.6. Future Growth Opportunities in the Asia and Rest of the World
28.7. Expected Increase in Number of Collaborations and Licensing Activity
28.8 Concluding Remarks

29. CONCLUSION

30. EXECUTIVE INSIGHTS
30.1. Chapter Overview
30.2. Antibody Solutions
30.2.1. Company Snapshot
30.2.2. John S Kenney, Founder and President (Q3 2023)

30.3. Adimab
30.3.1. Company Snapshot
30.3.3. Guy Van Meter, Chief Business Officer (Q3 2023)

30.4. ImmunoPrecise Antibodies
30.4.1. Company Snapshot
30.4.3. Kari Graber, Vice President of Commercial Services (Q3 2023)

30.5. Anonymous
30.5.1. Anonymous, Chief Business Officer (Q3 2023)

30.6. Abveris, Acquired by Twist Biosciences
30.6.1. Company Snapshot
30.6.2. Tracey Mullen, Former Chief Executive Officer (Q2 2020)

30.7. Nidus BioSciences
30.7.1. Company Snapshot
30.7.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)

30.8. AvantGen
30.8.1. Company Snapshot
30.8.2. Mark Kubik, Former Chief Business Officer (Q1 2020)

30.9. Single Cell Technology
30.9.1. Company Snapshot
30.9.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)

30.10. Distributed Bio
30.10.1. Company Snapshot
30.10.2. Giles Day, Co-Founder and Former Chief Executive Officer (Q2 2018)

30.11. AbCellera
30.11.1. Company Snapshot
30.11.2. Kevin Heyries, Co-Founder and Former Lead of Business Development Strategy (Q2 2018)

30.12. AbGenics Life Sciences
30.12.1. Company Snapshot
30.12.2. Sanjiban K Banerjee, Co-founder and Director (Q2 2018)

30.13. CDI Laboratories
30.13.1. Company Snapshot
30.13.2. Ignacio Pino, Co-founder and Chief Executive Officer (Q2 2017)

30.14. AP Biosciences
30.14.1. Company Snapshot
30.14.2. Jeng Her, Chief Executive Officer (Q2 2017)

30.15. YUMAB
30.15.1. Company Snapshot
30.15.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)

30.16. Antibody Solutions
30.16.1. Company Snapshot
30.16.2. Debra Valsamis, Business Development Associate (Q2 2017)

30.17. Ligand Pharmaceuticals
30.17.1. Company Snapshot
30.17.2. Christel Iffland, Senior Vice President (Q2 2017)

30.18. LakePharma
30.18.1. Company Snapshot
30.18.2. Aaron Sato, Former Chief Scientific Officer (Q2 2017)

31. APPENDIX 1: TABULATED DATA

32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape of Antibody Discovery Service Providers
Figure 4.2 Executive Summary: Market Landscape of Antibody Discovery Platform Providers
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Funding and Investment Analysis
Figure 4.5 Executive Summary: Market Sizing and Opportunity Analysis for Antibody Discovery Services
Figure 4.6 Executive Summary: Market Sizing and Opportunity Analysis for Antibody Discovery Platforms
Figure 5.1 Basic Structure of an Antibody
Figure 5.2 Historical Timeline of Antibody Development
Figure 5.3 Mechanism of Action of Antibodies
Figure 5.4 Applications of Antibodies
Figure 6.1 Overview of the Antibody Discovery Process
Figure 6.2 Antibody Discovery Process: Hybridoma Method
Figure 6.3 Antibody Discovery Process: Phage Display Method
Figure 6.4 Antibody Generation Using Transgenic Animals
Figure 6.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 6.6 Approval Timeline of Fully Human Monoclonal Antibodies
Figure 6.7 Discovery Methods of Fully Human Monoclonal Antibodies
Figure 7.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Figure 7.2 Antibody Discovery Service Providers: Distribution by Company Size
Figure 7.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Figure 7.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Figure 7.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Figure 7.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Figure 7.7 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 7.8 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered and Type of Antibody Discovery Method
Figure 7.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Services and Location of Headquarters
Figure 7.10 Antibody Discovery Service Providers: Analysis by Application Area
Figure 8.1 Competitiveness Analysis: Very Small Companies Offering Antibody Discovery Services
Figure 8.2 Competitiveness Analysis: Small Companies Offering Antibody Discovery Services
Figure 8.3 Competitiveness Analysis: Mid-sized Companies Offering Antibody Discovery Services
Figure 8.4 Competitiveness Analysis: Large Companies Offering Antibody Discovery Services
Figure 8.5 Regional Capability: Benchmarking of Players based in North America
Figure 8.6 Regional Capability: Benchmarking of Players based in Europe
Figure 8.7 Regional Capability: Benchmarking of Players based in Asia
Figure 9.1 ImmunoPrecise Antibodies: Annual Revenues, 2016-2022 (USD Million)
Figure 9.2 Abzena: Annual Revenues, 2016-2022 (GBP Million)
Figure 9.3 Fusion Antibodies: Annual Revenues, 2017-2022 (EUR Million)
Figure 9.4 Viva Biotech: Annual Revenues, 2016-2022 (RMB Million)
Figure 9.5 WuXi Biologics: Annual Revenues, 2016-2022 (RMB Billion)
Figure 10.1 Antibody Discovery Technologies: Distribution by Type of Antibody Discovered
Figure 10.2 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method
Figure 10.3 Antibody Discovery Technologies: Distribution by Animal Model Used
Figure 10.4 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Figure 10.5 Antibody Discovery Technologies: Distribution by Discovery Method and Type of Antibody Discovered
Figure 10.6 Antibody Discovery Technology Providers: Distribution by Year of Establishment
Figure 10.7 Antibody Discovery Technology Providers: Distribution by Company Size
Figure 10.8 Antibody Discovery Technology Providers: Distribution by Location of Headquarters
Figure 10.9 Most Active Players: Distribution by Number of Technologies
Figure 11.1 Competitiveness Analysis: Technologies Offered by Companies based in North America
Figure 11.2 Competitiveness Analysis: Technologies Offered by Companies based in Europe
Figure 11.3 Competitiveness Analysis: Technologies Offered by Companies based in Asia and Rest of the World
Figure 13.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2023
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Antibody
Figure 13.5 Most Active Players: Distribution by Number of Partnerships
Figure 13.6 Most Popular Technologies: Distribution by Number of Partnerships
Figure 13.7 Partnerships and Collaborations: Distribution by Geography
Figure 13.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2023
Figure 14.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 14.3 Funding and Investment Analysis: Distribution of Amount Invested by Year of Funding, 2016-2023 (USD Million)
Figure 14.4 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Funding Amount, 2016-2023 (USD Million)
Figure 14.5 Most Active Players: Distribution by Number of Funding Instances
Figure 14.6 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 14.7 Leading Investors: Distribution by Number of Funding Instances
Figure 14.8 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Type of Player
Figure 14.9 Funding and Investment Analysis: Distribution by Year-wise Amount Invested and Type of Player
Figure 14.1 0 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Establishment and Type of Player
Figure 14.1 1 Funding and Investment Analysis: Distribution by Geography
Figure 14.1 2 Funding and Investment Analysis: Concluding Remarks
Figure 15.1 Market Drivers
Figure 15.2 Market Restrainers
Figure 15.3 Market Opportunities
Figure 15.4 Market Challenges
Figure 16.1 Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 16.2 Global Antibody Discovery Services Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 16.3 Global Antibody Discovery Services Market, 2023-2035, Conservative Scenario (USD Million)
Figure 17.1 Antibody Discovery Services Market for Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.2 Antibody Discovery Services Market for Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.3 Antibody Discovery Services Market for Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.4 Antibody Discovery Services Market for Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.5 Antibody Discovery Services Market for Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.1 Antibody Discovery Services Market for Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.2 Antibody Discovery Services Market for Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.3 Antibody Discovery Services Market for Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.4 Antibody Discovery Services Market for Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.5 Antibody Discovery Services Market for Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.6 Antibody Discovery Services Market for Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.1 Antibody Discovery Services Market for Humanized Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.2 Antibody Discovery Services Market for Human Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.3 Antibody Discovery Services Market for Chimeric Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.4 Antibody Discovery Services Market for Murine Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.1 Antibody Discovery Services Market for Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.2 Antibody Discovery Services Market for Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.3 Antibody Discovery Services Market for Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.4 Antibody Discovery Services Market for Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.5 Antibody Discovery Services Market for Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.6 Antibody Discovery Services Market for Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.1 Antibody Discovery Services Market in North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.2 Antibody Discovery Services Market in Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.3 Antibody Discovery Services Market in Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.4 Antibody Discovery Services Market in Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.5 Antibody Discovery Services Market in Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.6 Antibody Discovery Services Market in Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 22.1 Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.2 Global Antibody Discovery Technologies Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 22.3 Global Antibody Discovery Technologies Market, 2023-2035, Conservative Scenario (USD Million)
Figure 23.1 Antibody Discovery Technologies Market for Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 23.2 Antibody Discovery Technologies Market for Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 23.3 Antibody Discovery Technologies Market for Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.1 Antibody Discovery Technologies Market in North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.2 Antibody Discovery Technologies Market in Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.3 Antibody Discovery Technologies Market in Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 25.1 Licensing Agreements: Distribution of Financial Components
Figure 25.2 Technology Licensing Deal: Payment Structure
Figure 26.1 Antibody Humanization Services and Platforms: SWOT Analysis
Figure 26.2 Antibody Humanization Services and Platforms: Strengths
Figure 26.3 Antibody Humanization Services and Platforms: Weaknesses
Figure 26.4 Antibody Humanization Services and Platforms: Opportunities
Figure 26.5 Antibody Humanization Services and Platforms: Threats
Figure 27.1 Humira®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.2 Keytruda®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.3 Stelara®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.4 Opdivo®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.5 Darzalex®: Annual Sales, 2016-2022 (CHF Million)
Figure 28.1 Future Opportunities Related to Upcoming Trends in Drug Discover

List Of Tables

Table 5.1 Antibody Isotypes: Key Features
Table 5.2 Mechanism of Action of Therapeutic Antibodies Against Different Target Classes
Table 5.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 7.1 Antibody Discovery Service Providers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 7.2 Antibody Discovery Service Providers: Information on Type of Services Offered
Table 7.3 Antibody Discovery Service Providers: Information on Type of Antibody Discovered
Table 7.4 Antibody Discovery Service Providers: Information on Type of Antibody Discovery Method
Table 7.5 Antibody Discovery Service Providers: Information on Animal Model Used
Table 7.6 Antibody Discovery Service Providers: Information on Application Area
Table 8.1 Regional Capability Analysis: Antibody Discovery Service Providers Based in North America
Table 8.2 Regional Capability Analysis: Antibody Discovery Service Providers Based in Europe
Table 8.3 Regional Capability Analysis: Antibody Discovery Service Providers Based in Asia
Table 9.1 List of Companies Profiled
Table 9.2 Abwiz Bio: Company Snapshot
Table 9.3 Abwiz Bio: Recent Developments and Future Outlook
Table 9.4 Aragen Bioscience: Company Snapshot
Table 9.5 Aragen Bioscience: Recent Developments and Future Outlook
Table 9.6 Creative Biolabs: Company Snapshot
Table 9.7 Creative Biolabs: Recent Developments and Future Outlook
Table 9.8 Distributed Bio: Company Snapshot
Table 9.9 Distributed Bio: Recent Developments and Future Outlook
Table 9.10 ImmunoPrecise Antibodies: Company Snapshot
Table 9.11 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 9.12 Integral Molecular: Company Snapshot
Table 9.13 Integral Molecular: Recent Developments and Future Outlook
Table 9.14 LakePharma: Company Snapshot
Table 9.15 LakePharma: Recent Developments and Future Outlook
Table 9.16 Abzena: Company Snapshot
Table 9.17 Abzena: Recent Developments and Future Outlook
Table 9.18 BIOTEM: Company Snapshot
Table 9.19 BIOTEM: Recent Developments and Future Outlook
Table 9.20 PX'Therapeutics: Company Snapshot
Table 9.21 PX'Therapeutics: Recent Developments and Future Outlook
Table 9.22 ChemPartner: Company Snapshot
Table 9.23 ChemPartner: Recent Developments and Future Outlook
Table 9.24 Viva Biotech: Company Snapshot
Table 9.25 Viva Biotech: Recent Developments and Future Outlook
Table 9.26 WuXi Biologics: Company Snapshot
Table 9.27 WuXi Biologics: Recent Developments and Future Outlook
Table 10.1 Antibody Discovery Technologies: Information on Type of Antibody Discovered
Table 10.2 Antibody Discovery Service Technologies: Information on Type of Antibody Discovery Method
Table 10.3 Antibody Discovery Service Technologies: Information on Animal Model Used
Table 10.4 Antibody Discovery Service Technologies: Information on Location of Headquarters of Developer
Table 10.5 Antibody Discovery Platform Providers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 12.1 List of Companies Profiled
Table 12.2 Ablexis: Company Snapshot
Table 12.3 Ablexis: Antibody Discovery Platform Portfolio
Table 12.4 Ablexis: Recent Developments and Future Outlook
Table 12.5 Creative Biolabs: Company Snapshot
Table 12.6 Creative Biolabs: Antibody Discovery Platform Portfolio
Table 12.7 Creative Biolabs: Recent Developments and Future Outlook
Table 12.8 Genmab: Company Snapshot
Table 12.9 Genmab: Antibody Discovery Platform Portfolio
Table 12.10 Genmab: Recent Developments and Future Outlook
Table 12.11 Harbour BioMed: Company Snapshot
Table 12.12 Harbour BioMed: Antibody Discovery Platform Portfolio
Table 12.13 Harbour BioMed: Recent Developments and Future Outlook
Table 12.14 Immunome: Company Snapshot
Table 12.15 Immunome: Antibody Discovery Platform Portfolio
Table 12.16 Immunome: Recent Developments and Future Outlook
Table 12.17 Isogenica: Company Snapshot
Table 12.18 Isogenica: Antibody Discovery Platform Portfolio
Table 12.19 Isogenica: Recent Developments and Future Outlook
Table 12.20 Kymab: Company Snapshot
Table 12.21 Kymab: Antibody Discovery Platform Portfolio
Table 12.22 Kymab: Recent Developments and Future Outlook
Table 12.23 Ligand Pharmaceuticals: Company Snapshot
Table 12.24 Ligand Pharmaceuticals: Antibody Discovery Platform Portfolio
Table 12.25 Ligand Pharmaceuticals: Recent Developments and Future Outlook
Table 12.26 MorphoSys: Company Snapshot
Table 12.27 MorphoSys: Antibody Discovery Platform Portfolio
Table 12.28 MorphoSys: Recent Developments and Future Outlook
Table 13.1 Antibody Discovery Service and Platform Providers: List of Partnerships and Collaboration, 2015-2023
Table 14.1 Antibody Discovery Service and Platform Providers: List of Funding Instances, 2016-2023
Table 24.1 Developmental / Regulatory Milestones
Table 24.2 Antibody Discovery Platforms: Average Upfront and Average Milestone Payments (USD Million)
Table 25.1 Approved Monoclonal Antibodies: Information on Affinity
Table 25.2 Antibody Humanization: List of Service Providers
Table 26.1 List of Top Ten Selling Therapeutic Antibodies, 2022
Table 29.1 Antibody Solutions: Company Snapshot
Table 29.2 A dimab: Company Snapshot
Table 29.3 I mmunoPrecise Antibodies: Company Snapshot
Table 29.4 A bveris Antibody: Company Snapshot
Table 29.5 N idus BioSciences: Company Snapshot
Table 29.6 A vantGen: Company Snapshot
Table 29.7 S ingle Cell Technology: Company Snapshot
Table 29.8 D istributed Bio: Company Snapshot
Table 29.9 AbCellera: Company Snapshot
Table 29.10 AbGenics Life Sciences: Company Snapshot
Table 29.11 CDI Laboratories: Company Snapshot
Table 29.12 AP Biosciences: Company Snapshot
Table 29.13 YUMAB: Company Snapshot
Table 29.14 Antibody Solutions: Company Snapshot
Table 29.15 Ligand Pharmaceuticals: Company Snapshot
Table 29.16. LakePharma: Company Snapshot
Table 30.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Table 30.2 Antibody Discovery Service Providers: Distribution by Company Size
Table 30.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Table 30.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 30.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 30.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 30.7 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 30.8 A ntibody Discovery Service Providers: Distribution by Type of Antibody Discovered and Type of Antibody Discovery Method
Table 30.9 A ntibody Discovery Service Providers: Distribution by Type of Antibody Discovery Services and Location of Headquarters
Table 30.10 Antibody Discovery Service Providers: Analysis by Application Area
Table 30.11 ImmunoPrecise Antibodies: Annual Revenues, 2016-2022 (USD Million)
Table 30.12 Abzena: Annual Revenues, 2016-2022 (GBP Million)
Table 30.13 Fusion Antibodies: Annual Revenues, 2017-2022 (EUR Million)
Table 30.14 Viva Biotech: Annual Revenues, 2016-2022 (RMB Million)
Table 30.15 WuXi Biologics: Annual Revenues, 2016-2022 (RMB Billion)
Table 30.16 Antibody Discovery Technologies: Distribution by Type of Antibody Discovered
Table 30.17 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method
Table 30.18 Antibody Discovery Technologies: Distribution by Animal Model Used
Table 30.19 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Table 30.20 Antibody Discovery Technologies: Distribution by Discovery Method and Type of Antibody Discovered
Table 30.21 Antibody Discovery Technology Providers: Distribution by Year of Establishment
Table 30.22 Antibody Discovery Technology Providers: Distribution by Company Size
Table 30.23 Antibody Discovery Technology Providers: Distribution by Location of Headquarters
Table 30.24 Most Active Players: Distribution by Number of Technologies
Table 30.25 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2023
Table 30.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 30.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Table 30.28 Partnerships and Collaborations: Distribution by Type of Antibody
Table 30.29 Most Active Players: Distribution by Number of Partnerships
Table 30.30 Most Popular Technologies: Distribution by Number of Partnerships
Table 30.31 Partnerships and Collaborations: Distribution by Geography
Table 30.32 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 30.33 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2023
Table 30.34 Funding and Investment Analysis: Distribution by Type of Funding
Table 30.35 Funding and Investment Analysis: Distribution of Amount Invested by Year of Funding, 2016-2023 (USD Million)
Table 30.36 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Funding Amount, 2016-2023 (USD Million)
Table 30.37 Most Active Players: Distribution by Number of Funding Instances
Table 30.38 Most Active Players: Distribution by Amount Invested (USD Million)
Table 30.39 Leading Investors: Distribution by Number of Funding Instances
Table 30.40 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Type of Player
Table 30.41 Funding and Investment Analysis: Distribution by Year-wise Amount Invested and Type of Player
Table 30.42 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Establishment and Type of Player
Table 30.43 Funding and Investment Analysis: Distribution by Geography
Table 30.44 Global Antibody Discovery Services Market, Historical Trends, 2017-2022 (USD Million)
Table 30.45 Global Antibody Discovery Services Market, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 30.46 Antibody Discovery Services Market for Antigen Designing, Historical Trends 2017-2022 (USD Million)
Table 30.47 Antibody Discovery Services Market for Antigen Designing, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.48 Antibody Discovery Services Market for Hit Generation, Historical Trends, 2017-2022 (USD Million)
Table 30.49 Antibody Discovery Services Market for Hit Generation, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.50 Antibody Discovery Services Market for Lead Selection, Historical Trends, 2017-2022 (USD Million)
Table 30.51 Antibody Discovery Services Market for Lead Selection, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.52 Antibody Discovery Services Market for Lead Optimization, Historical Trends, 2017-2022 (USD Million)
Table 30.53 Antibody Discovery Services Market for Lead Optimization, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.54 Antibody Discovery Services Market for Lead Characterization, Historical Trends, 2017-2022 (USD Million)
Table 30.55 Antibody Discovery Services Market for Lead Characterization, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.56 Antibody Discovery Services Market for Phage Display, Historical Trends, 2017-2022 (USD Million)
Table 30.57 Antibody Discovery Services Market for Phage Display, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.58 Antibody Discovery Services Market for Yeast Display, Historical Trends, 2017-2022 (USD Million)
Table 30.59 Antibody Discovery Services Market for Yeast Display, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.60 Antibody Discovery Services Market for Hybridoma Method, Historical Trends, 2017-2022 (USD Million)
Table 30.61 Antibody Discovery Services Market for Hybridoma Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USDMillion)
Table 30.62 Antibody Discovery Services Market for Transgenic Animal based Method, Historical Trends, 2017-2022 (USD Million)
Table 30.63 Antibody Discovery Services Market for Transgenic Animal based Method, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.64 Antibody Discovery Services Market for Single Cell based Method, Historical Trends, 2017-2022 (USD Million)
Table 30.65 Antibody Discovery Services Market for Single Cell based Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.66 Antibody Discovery Services Market for Other Antibody Discovery Method, Historical Trends, 2017-2022 (USD Million)
Table 30.67 Antibody Discovery Services Market for Other Antibody Discovery Method, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.68 Antibody Discovery Services Market for Humanized Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.69 Antibody Discovery Services Market for Humanized Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.70 Antibody Discovery Services Market for Human Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.71 Antibody Discovery Services Market for Human Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USDMillion)
Table 30.72 Antibody Discovery Services Market for Chimeric Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.73 Antibody Discovery Services Market for Chimeric Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USDMillion)
Table 30.74 Antibody Discovery Services Market for Murine Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.75 Antibody Discovery Services Market for Murine Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.76 Antibody Discovery Services Market for Oncological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.77 Antibody Discovery Services Market for Oncological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.78 Antibody Discovery Services Market for Immunological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.79 Antibody Discovery Services Market for Immunological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.80 Antibody Discovery Services Market for Infectious Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.81 Antibody Discovery Services Market for Infectious Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.82 Antibody Discovery Services Market for Neurological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.83 Antibody Discovery Services Market for Neurological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.84 Antibody Discovery Services Market for Cardiovascular Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.85 Antibody Discovery Services Market for Cardiovascular Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.86 Antibody Discovery Services Market for Other Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.87 Antibody Discovery Services Market for Other Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USDMillion)
Table 30.88 Antibody Discovery Services Market in North America, Historical Trends, 2017-2022 (USD Million)
Table 30.89 Antibody Discovery Services Market in North America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USDMillion)
Table 30.90 Antibody Discovery Services Market in Europe, Historical Trends, 2017-2022 (USD Million)
Table 30.91 Antibody Discovery Services Market in Europe, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.92 Antibody Discovery Services Market in Asia, Historical Trends, 2017-2022 (USD Million)
Table 30.93 Antibody Discovery Services Market in Asia, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.94 Antibody Discovery Services Market in Latin America, Historical Trends, 2017-2022 (USD Million)
Table 30.95 Antibody Discovery Services Market in Latin America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USDMillion)
Table 30.96 Antibody Discovery Services Market in Middle East and North Africa, Historical Trends, 2017-2022 (USD Million)
Table 30.97 Antibody Discovery Services Market in Middle East and North Africa, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.98 Antibody Discovery Services Market in Rest of the World, Historical Trends, 2017-2022 (USD Million)
Table 30.99 Antibody Discovery Services Market in Rest of the World, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USDMillion)
Table 30.100 Global Antibody Discovery Technologies Market, Historical Trends (2017-2022)
Table 30.101 Global Antibody Discovery Technologies Market, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.102 Antibody Discovery Technologies Market for Monoclonal Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.103 Antibody Discovery Technologies Market for Monoclonal Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.104 Antibody Discovery Technologies Market for Bispecific Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.105 Antibody Discovery Technologies Market for Bispecific Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and OptimisticScenarios (USD Million)
Table 30.106 Antibody Discovery Technologies Market for Other Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.107 Antibody Discovery Technologies Market for Other Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.108 Antibody Discovery Technologies Market in North America, Historical Trends, 2017-2022 (USD Million)
Table 30.109 Antibody Discovery Technologies Market in North America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios(USD Million)
Table 30.110 Antibody Discovery Technologies Market in Europe, Historical Trends, 2017-2022 (USD Million)
Table 30.111 Antibody Discovery Technologies Market in Europe, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.112 Antibody Discovery Technologies Market in Asia, Historical Trends, 2017-2022 (USD Million)
Table 30.113 Antibody Discovery Technologies Market in Asia, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.114 Humira®: Annual Sales, 2016-2022 (USD Billion)
Table 30.115 Keytruda®: Annual Sales, 2016-2022 (USD Billion)
Table 30.116 Stelara®: Annual Sales, 2016-2022 (USD Billion)
Table 30.117 Opdivo®: Annual Sales, 2016-2022 (USD Billion)
Table 30.118 Darzalex®: Annual Sales, 2016-2022 (CHF Million)

List Of Companies

  1. 2BScientific
  2. 3SBio
  3. AAT Bioquest
  4. Ab Initio Biotherapeutics
  5. Ab Studio
  6. ABBA Therapeutics
  7. AbBioSci
  8. Abbiotec
  9. AbbVie
  10. Abcalis
  11. Abcam
  12. AbCellera
  13. Abcentra (formerly CardioVax)
  14. Abcepta
  15. AbCheck
  16. Abclonal
  17. Abcore
  18. ABDYS
  19. Abeome
  20. Abexxa Biologics
  21. ABGENEX
  22. AbGenics Life Sciences
  23. Abilita Bio
  24. ABL Bio
  25. Ablexis
  26. Ablynx
  27. Abnova
  28. Abpro
  29. AbSano
  30. Absci
  31. Absea Biotechnology
  32. Absolute Antibody
  33. Abterra Biosciences
  34. AbTherx
  35. AbTis
  36. Abveris (Acquired by Twist Bioscience)
  37. AbVision
  38. Abwiz Bio
  39. Abzena
  40. Abzyme Therapeutics
  41. AC Immune
  42. Acceleron Pharma
  43. Accurus Biosciences
  44. AceMab
  45. Achaogen
  46. Aclys Bio
  47. ACROBiosystems
  48. ACYTE Biotech
  49. Adagene
  50. Adaptate Biotherapeutics
  51. ADC Therapeutics
  52. Adcentrx Therapeutics
  53. Adimab
  54. AdipoGen Life Sciences
  55. Administration for Strategic Preparedness and Response (ASPR)
  56. Aduro Biotech
  57. AffinityImmuno
  58. AFSBio
  59. Aganitha
  60. Agency for Science, Technology and Research
  61. Agenus
  62. Agro-Bio
  63. AIMM Therapeutics
  64. Aimmune Therapeutics
  65. Akeagen
  66. Akeso
  67. Akeso Biopharma
  68. Alacrita
  69. Alamar Biosciences
  70. Aldevron
  71. Alector
  72. Alexion
  73. AlivaMab Discovery Services
  74. Alligator Bioscience
  75. Allogene Therapeutics
  76. Alloy Therapeutics
  77. Almirall
  78. AlpalifeBio
  79. ALSA Ventures
  80. Alvaxa Biosciences (Acquired by Sensei Biotherapeutics)
  81. ALX Oncology
  82. Alytas Therapeutics
  83. Amerigo Scientific
  84. Amgen
  85. AMSBIO
  86. Analytics Engine
  87. AnaptysBio
  88. Angios
  89. Annoron Biotechnology
  90. Antengene
  91. Antibodies Incorporated
  92. Antibodies-online
  93. Antibody Analytics
  94. Antibody Design Labs
  95. Antibody Production Services (A division of Life Science Group)
  96. Antibody Solutions
  97. Antiverse
  98. AP Biosciences
  99. Apexigen
  100. APITBIO
  101. Applied Biological Materials
  102. Applied StemCell
  103. AprilBio
  104. Aptevo Therapeutics
  105. Aragen Life Sciences
  106. Aravive
  107. Arctoris
  108. Arcus Biosciences
  109. argenx
  110. Aridis Pharmaceuticals
  111. aRNAy Sciences
  112. Aro Biotherapeutics
  113. Aronora
  114. Arsanis
  115. Artizan Biosciences
  116. Arvinas
  117. ARVYS Proteins
  118. AskGene Pharma
  119. Astellas
  120. AstraZeneca
  121. aTen Therapeutics
  122. Atlantis Bioscience
  123. Atlas Venture
  124. Atreca
  125. ATUM
  126. Aureka
  127. Aurigene Pharmaceutical Services
  128. Autolus Therapeutics
  129. Automated Lab Solutions
  130. AvantGen
  131. Aviva Systems Biology
  132. AxioMx
  133. Axxora
  134. Bayer
  135. BBI Group
  136. BBI Solutions
  137. Beckman Coulter
  138. BeiGene
  139. BenevolentAI
  140. Berkeley Lights
  141. Betta Pharmaceuticals
  142. Bhami's Research Laboratories
  143. Bhat Bio-tech India
  144. Big Cypress Acquisition
  145. BigHat Biosciences
  146. Bill & Melinda Gates Foundation
  147. Bill & Melinda Gates Medical Research Institute
  148. Bio Bench
  149. BioArctic
  150. BioAtla
  151. BioBench Solutions
  152. Biochem Pharma
  153. BioClue (Acquired by ImmunoPrecise Antibodies)
  154. Bio-Connect
  155. Biocure Technology
  156. Biocytogen
  157. BioD
  158. BioDuro-Sundia
  159. Biogen
  160. BioHub International Trade
  161. Bioinborn Scientific
  162. Biointron
  163. BioInvent
  164. BioKey (Acquired by ImmunoPrecise Antibodies)
  165. Biologics International
  166. Biomolecular Discovery Services
  167. BioNTech
  168. Bioqube Ventures
  169. Bio-Rad Laboratories
  170. Biosion
  171. BioStrand (Acquired by ImmunoPrecise Antibodies)
  172. Biosynth
  173. Biotalys
  174. Bio-Techne
  175. Biotecnol
  176. BIOTEM
  177. BioTeZ
  178. Biotheus
  179. BioTickle
  180. BioVision
  181. BioXpress Therapeutics
  182. Bird Rock Bio
  183. Blue Sky BioServices (Acquired by LakePharma)
  184. BlueBird Bio
  185. Bluejay Therapeutics
  186. Boan Biotech
  187. Boehringer Ingelheim
  188. Bolt Biotherapeutics
  189. Boster Biological Technology
  190. Bristol Myers Squibb
  191. Broteio Pharma
  192. CALIXAR
  193. Cambridge Research Biochemicals
  194. CANbridge Pharmaceuticals
  195. Cancer Research UK
  196. Cantargia
  197. Capra Science
  198. Capralogics
  199. Caris Life Sciences
  200. Carterra
  201. CASI Pharmaceuticals
  202. Catalent Biologics
  203. Cayman Chemical
  204. CD ComputaBio
  205. CDI Laboratories
  206. Celexion
  207. Celgene
  208. Cell Signaling Technology
  209. Celltrion
  210. Celros Biotech
  211. Celsius Therapeutics
  212. Centre for Applied Medical Research
  213. Centers for Disease Control and Prevention
  214. Charles River
  215. ChemBio Discovery Solutions
  216. ChemPartner
  217. Cherry Biolabs 
  218. Chia Tai Tianqing Pharmaceutical
  219. Chiome Bioscience
  220. Chipscreen Biosciences
  221. ChromoTek
  222. Chugai Pharmabody Research
  223. Chugai Pharmaceutical
  224. Cidara Therapeutics
  225. Cilag
  226. Citryll
  227. City of Hope
  228. Cizzle Biotechnology
  229. Clayton Biotechnologies
  230. Click Chemistry Tools
  231. Clínica Universidad de Navarra
  232. CliniSciences
  233. Columbia University Irving Medical Center
  234. Compass Therapeutics
  235. Context Therapeutics
  236. Coronavirus Immunotherapy Consortium
  237. Corvidia Therapeutics
  238. Cosmo Bio
  239. CP Qingdao
  240. Creative Bioarray
  241. Creative Biolabs
  242. Creative Biostructure
  243. Creative Diagnostics
  244. Crescendo Biologics
  245. Crystal Bioscience
  246. CSL Behring
  247. Cstone Pharmaceuticals
  248. CureVac
  249. Curia
  250. CUSABIO
  251. Cyclogenix
  252. Cygnus Technologies
  253. DAAN Biotherapeutics
  254. Daiichi Sankyo
  255. Dako
  256. Dana-Farber Cancer Institute
  257. Danaher
  258. DaTaMabs
  259. DBA Italia
  260. Deerfield Discovery and Development
  261. Denali Therapeutics
  262. DetaiBio
  263. Diagnostic BioSystems
  264. Diatheva
  265. Digital Proteomics
  266. Dingkang Biology
  267. discoveric bio
  268. Distributed Bio
  269. DJS Antibodies
  270. Dragonfly Therapeutics
  271. E2DG
  272. Eisai
  273. Elabscience
  274. Eli Lilly and Company
  275. Elpis Biopharmaceuticals
  276. Emergent BioSolutions
  277. Empirico
  278. e-nnovation Life Sciences
  279. ENPICOM
  280. Enthera
  281. Entos Pharmaceuticals
  282. Envigo
  283. EpimAb Biotherapeutics
  284. EQRx
  285. Erasmus MC
  286. Ethris
  287. Eureka Therapeutics
  288. Eurofins Discovery
  289. Everest Medicines
  290. Evitria
  291. Evotec
  292. EVQLV
  293. Exelixis
  294. ExeVir Bio
  295. Exiris
  296. exonbio
  297. Exscientia
  298. Faculta (Acquired by Prosci)
  299. FairJourney Biologics
  300. Faron Pharmaceuticals
  301. Ferring Pharmaceuticals
  302. FibroGen
  303. Five Prime Therapeutics
  304. Fluoroprobes
  305. Forty Seven
  306. Foundery Innovations
  307. Fred Hutchinson Cancer Center
  308. Frederick National Laboratory for Cancer Research
  309. French Institute of Health and Medical Research
  310. Frugi Biotechnology
  311. Funakoshi
  312. Fusion Antibodies
  313. Fusion Pharmaceuticals
  314. G&P Biosciences
  315. G.CLIPS BIOTECH
  316. Gator Bio
  317. Genagon Therapeutics
  318. Gene Techno Science
  319. GeneBeyond
  320. Genedata
  321. GeneFrontier 
  322. GENEWIZ (Acquired by Azenta Life Sciences)
  323. GeneX India Bioscience
  324. Genmab
  325. Genome Institute of Singapore
  326. Genor Biopharma
  327. GenoSafe
  328. Genovac
  329. GenScript
  330. Genuv
  331. Gen-Y Biologics
  332. GigaGen
  333. Gilead Sciences
  334. Gladstone Institutes
  335. Glenmark Pharmaceuticals
  336. Glythera
  337. Gmax Biopharm
  338. Government of British Columbia
  339. Government of Canada
  340. Green Mountain Antibodies
  341. Grenoble Hospital
  342. GSK
  343. Gustave Roussy
  344. GV20 Therapeutics
  345. HaemaLogiX
  346. Hangzhou Qiantang River Electric
  347. Harbour Antibodies
  348. Harbour BioMed
  349. Harpoon Therapeutics
  350. HD Biosciences
  351. Helix BioPharma
  352. Jiangsu Hengrui Pharmaceuticals
  353. Henlix Biotech
  354. Heptares Therapeutics
  355. HI-Bio
  356. HiFiBiO Therapeutics
  357. Himalaya Therapeutics
  358. H-Immune Therapeutics (Acquired by HiFiBiO Therapeutics)
  359. HJB
  360. Hölzel Diagnostika Handels
  361. Horizon Discovery
  362. Hualan Genetic Engineering
  363. Hubrecht Institute
  364. Humanigen
  365. Hummingbird Bioscience
  366. I&L Biosystems
  367. i2 Pharmaceuticals
  368. IAMA France
  369. IASO Biotherapeutics
  370. Ibex Biosciences
  371. iBio
  372. Icagen
  373. Icosagen
  374. IGEM Therapeutics
  375. IgGenix
  376. IGM Biosciences
  377. I-Mab Biopharma
  378. iMetabolic Biopharma
  379. Immatics Biotechnologies
  380. Immorna
  381. Immune Biosolutions
  382. Immune Pharmaceuticals
  383. Immunitas Therapeutics
  384. immunitoAI
  385. Immunochem
  386. ImmunoChina Pharmaceuticals
  387. ImmunoGenes
  388. Immunome
  389. Immunomic Therapeutics
  390. ImmunoPrecise Antibodies
  391. ImmunoQure
  392. Immusmol
  393. Immutep
  394. In-Cell-Art
  395. Incyte
  396. Indivumed
  397. InflaRx
  398. Inhibrx
  399. Innate Pharma
  400. InnoBation Bio
  401. Innovagen
  402. Innovative Targeting Solutions
  403. Innovent
  404. Inotiv
  405. InstaDeep
  406. Institute for Research in Biomedicine
  407. Intarcia Therapeutics (Acquired by i2o Therapeutics)
  408. Integral Molecular
  409. Integrated DNA Technologies
  410. International Livestock Research Institute
  411. Invenra
  412. Invetx
  413. IONTAS
  414. IRBM
  415. Isogenica
  416. Italian National Institute of Health
  417. ITBMed
  418. iTeos Therapeutics
  419. Janssen
  420. Jazz Pharmaceuticals
  421. Johnson & Johnson Innovation
  422. Jotbody
  423. Jounce Therapeutics
  424. Juno Therapeutics
  425. Junshi Biosciences
  426. Just Biotherapeutics
  427. JW Pharmaceuticals
  428. Kadmon
  429. Kairos Therapeutics
  430. KAKEN PHARMACEUTICAL
  431. Kanwhish Biotechnology
  432. KareBay Biochem
  433. Karolinska University Hospital
  434. Kemp Proteins
  435. KGbio
  436. Kite Pharma
  437. KMD Bioscience
  438. Kodiak Sciences
  439. KYinno
  440. Kymab
  441. Kyoritsuseiyaku
  442. Kyowa Kirin
  443. La Jolla Institute for Immunology
  444. LabGenius
  445. Labtoo
  446. LakePharma
  447. LamKap Bio
  448. LAMPIRE Biological Labs
  449. Lanier Biotherapeutics
  450. Lava Therapeutics
  451. Leadgene Biomedical
  452. Leading Biology
  453. Leads Biolabs
  454. LegoChem Biosciences
  455. Leica Microsystems
  456. LEO Pharma
  457. LG Chem
  458. LifeArc
  459. LifeTein
  460. Ligand Pharmaceuticals
  461. Light Chain Bioscience
  462. Lineage Cell Therapeutics
  463. Lonza
  464. Loxo Oncology
  465. Lunaphore
  466. Lundbeck
  467. Luye Pharma
  468. MAB Discovery
  469. MabGenesis
  470. Mablytics
  471. Mabpharm
  472. MAbSilico
  473. mAbsolve
  474. MabSpace Biosciences
  475. Mabtech
  476. MabVax
  477. Mabworks
  478. MacroGenics
  479. Magenta Therapeutics
  480. Maine Biotechnology Services
  481. Maravai LifeSciences
  482. Masaachusetts General Hospital
  483. Mass Biologics
  484. Maverick Therapeutics
  485. Beijing Mede Taikang Biotechnology 
  486. MedAbome
  487. MedGenome
  488. Medicilon
  489. MedImmune
  490. Medix Biochemica
  491. MEDx
  492. MEMO Therapeutics
  493. Memorial Sloan Kettering Cancer Center
  494. Merck
  495. Merus
  496. Mila
  497. MI-mAbs
  498. Mithra Pharmaceuticals
  499. Mitsubishi Tanabe Pharma Corporation
  500. Moderna
  501. ModeX Therapeutics
  502. ModiQuest
  503. Molcure
  504. Molecular Devices
  505. Molecular Templates
  506. MolMed
  507. Mologic
  508. Moradec
  509. MorphoSys
  510. Mount Sinai
  511. MSD
  512. MSM Protein Technologies
  513. Mycenax Biotech
  514. Myrio Therapeutics
  515. Mythic Therapeutics
  516. Nanjing Chia-Tai Tianqing Pharmaceutical Company
  517. Nanocarry Therapeutics
  518. NanoCellect Biomedical
  519. NanoString Technologies
  520. National Cancer Institute
  521. National Research Council of Canada's Human Health Therapeutics Research Centre
  522. National, Heart, Lung, and Blood Institute
  523. NaturalAntibody
  524. Nautilus Systems
  525. NB Health Laboratory
  526. NBE Therapeutics
  527. Nelum
  528. NeoBiotechnologies
  529. NeoClone
  530. Neon Therapeutics
  531. neoX Biotech
  532. Neurimmune
  533. Nexum
  534. Nidus MB Technologies
  535. Nidus BioSciences
  536. Nkarta
  537. Nona BioSciences
  538. Nordic Society of Gynaecological Oncology
  539. Normunity
  540. North Dakota State University
  541. Northway Biotech
  542. NovaRock Biotherapeutics
  543. Novartis
  544. Novo Holdings
  545. Novo Nordisk
  546. Numab Therapeutics
  547. NYU Langone Health
  548. Oak BioSciences
  549. Oblique Therapeutics
  550. Olympic Protein Technologies
  551. OmniAb
  552. OncoC4
  553. OncoOne
  554. OncoResponse
  555. Oncothyreon
  556. Onena Medicines
  557. Ono Pharmaceuticals
  558. Open Monoclonal Technology
  559. Optimeos Life Sciences
  560. OREGA Biotech
  561. OriCell
  562. OriGene Technologies
  563. OriMAbs
  564. Orion
  565. OSE Immunotherapeutics
  566. Ossianix
  567. Oxford Biomedica
  568. OXGENE
  569. Pandion Therapeutics
  570. Panoply Bio
  571. Paragon Therapeutics
  572. Pascal Biosciences
  573. Pediatric Brain Tumor Consortium 
  574. Penn Medicine
  575. PerkinElmer
  576. Perseus Proteomics
  577. Pfizer
  578. pH Pharma
  579. Phanes Therapeutics
  580. PharmAbcine
  581. PharmAbs
  582. PharmaEssentia Innovation Research Center
  583. PharmaLegacy
  584. Pharmsynthez
  585. Pierre Fabre
  586. Pinteon Therapeutics
  587. Pioneering Medicines
  588. Pionyr Immunotherapeutics
  589. Potenza Therapeutics
  590. Precision Antibody
  591. Prellis Biologics
  592. ProMab Biotechnologies
  593. Prometheus Authors
  594. Prosci
  595. Protein Alternatives
  596. Proteogenix
  597. ProteoNic
  598. ProtTech
  599. Purdue Pharma
  600. Pure Biologics
  601. PX'Therapeutics
  602. QIMR Berghofer Medical Research Institute
  603. QoolAbs
  604. Quadira Biosciences
  605. Queen's University
  606. Rallybio
  607. Rapid Novor
  608. RayBiotech
  609. RD Biotech
  610. ReCentrics Biotechnology
  611. Regeneron Pharmaceuticals
  612. Resonant Therapeutics
  613. Retrogenix
  614. RevMab Biosciences
  615. Revolve Biotechnologies
  616. Rezolute
  617. Roche
  618. Rockland Immunochemicals
  619. RubrYc Therapeutics
  620. Rx Biosciences
  621. RxBiologics
  622. SAb Biotherapeutics
  623. Saccharo
  624. Salipro Biotech
  625. San Diego Biomedical Research Institute
  626. Sanders Tri-Institutional Therapeutics Discovery Institute
  627. Sanofi
  628. Sanyou Biopharmaceuticals
  629. Sartorius
  630. SBH Sciences
  631. Scandion Oncology
  632. Scotia Biologics
  633. Sea Lane Biotechnologies
  634. Selecxine
  635. Sema4
  636. Sensei Biotherapeutics
  637. Serum Institute of India
  638. Servier
  639. Severance Hospital
  640. Sevion Therapeutics
  641. Shanghai Henlius Biotech
  642. Shanghai KangaBio
  643. Shanghai Pidu Biotechnology
  644. Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry RAS
  645. Shire
  646. Sichuan Kelun-Biotech Biopharmaceutical
  647. Siegfried Holding
  648. Simcere
  649. Simon Fraser University
  650. Single Cell Technology
  651. Sino Biological
  652. Sinobioway
  653. Sinopharm
  654. SmartPharm Therapeutics
  655. Sorrento Therapeutics
  656. SOTIO
  657. SouthernBiotech
  658. Specialised Therapeutics
  659. Specifica 
  660. Sphere Fluidics
  661. Stanford University
  662. Straterx
  663. Summit Therapeutics
  664. Sunshine Guojian
  665. Surface Oncology
  666. Surrozen
  667. Sutro Biopharma
  668. Suzhou Bright Scistar Biotechnology Company
  669. Syd Labs
  670. Symphogen
  671. Synaffix
  672. Synbio Technologies
  673. Syngene
  674. Synthelis
  675. Tachyon Therapeutics
  676. Takeda
  677. Tanabe Research Laboratories
  678. Tasgen Biotech (Acquried by I-Mab Biopharma)
  679. Tasly Biopharmaceuticals
  680. Taurus Biosciences
  681. TC BioPharm
  682. Technical University of Denmark
  683. Telesis Bio
  684. Telix Pharmaceuticals
  685. Tempus Labs
  686. TeneoBio
  687. TESARO
  688. Tetra Partner Network
  689. Tetragenetics
  690. Teva Pharmaceuticals
  691. TG Therapeutics
  692. The Antibody Company
  693. The Wistar Institute
  694. Theraclone Sciences
  695. Theranyx
  696. ThermoFisher Scientific
  697. Third Venture Biopharma
  698. ThromboGenics
  699. Tizona Therapeutics
  700. Tmunity Therapeutics
  701. Torch Biosciences
  702. TRACON Pharmaceuticals
  703. TRANSCENTA
  704. Transgene
  705. TRIANNI
  706. Tsinghua University
  707. Tubulis
  708. Twist Bioscience
  709. U.S. Naval Medical Research Unit No. 3
  710. UCLA Technology Development Group
  711. Universiti Sains Malaysia
  712. University College London
  713. University of Manchester
  714. University of Oxford
  715. University of Pennsylvania
  716. University of Southampton
  717. University of Surrey
  718. University of Texas MD Anderson Cancer Center
  719. University of Tokyo
  720. University of Zurich
  721. U-Protein (Acquired by ImmunoPrecise Antibodies)
  722. Utrecht University
  723. Vaccinex
  724. ValenzaBio (Acquired by ACELYRIN)
  725. Vall d’Hebron Institute of Oncology
  726. Valneva
  727. VBI Vaccines
  728. VectorB2B
  729. venBio Partners
  730. VERAXA Biotech
  731. Vir Biotechnology
  732. ViralClear Pharmaceuticals
  733. Visterra
  734. Viva Biotech
  735. Voyager Therapeutics
  736. Washington University
  737. Washington University School of Medicine
  738. Westlake Pharmaceuticals Services
  739. Westlake Therapeutics
  740. Wisconsin Alumni Research Foundation
  741. Worg Pharmaceuticals
  742. WuXi AppTec
  743. WuXi Biologics
  744. WuXi STA
  745. Wyss Institute
  746. XBiotech
  747. xCella Biosciences
  748. X-Chem
  749. Xencor
  750. XOMA
  751. Y- Biologics
  752. Yale Cancer Center
  753. Yangyang
  754. YenZym Antibodies
  755. Yinuoke
  756. Ymmunobio
  757. YUMAB
  758. Yurogen Biosystems
  759. Zai Lab
  760. Zebra Biologics
  761. Zhejiang Doer Biologics
  762. Zhejiang Teruisi Biopharmaceuticals
  763. Zoetis
  764. ZoonBio Biotechnology
  765. Zumutor Biologics
  766. Zydus
  767. Zymeworks

Source 1: https://www.pharmasalmanac.com/articles/what-do-you-consider-the-biggest-challenge-that-the-pharma/biopharma-industry-currently-faces
Source 2: https://www.sciencedirect.com/science/article/pii/S2049080114000624

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com